 Drug Resistance, Viral
"Drug Resistance, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation.
| Descriptor ID |
D024882
|
| MeSH Number(s) |
G06.225.420 G06.920.225 G07.690.773.984.269.420
|
| Concept/Terms |
Drug Resistance, Viral- Drug Resistance, Viral
- Drug Resistances, Viral
- Antiviral Drug Resistance
- Antiviral Drug Resistances
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Viral".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Viral".
This graph shows the total number of publications written about "Drug Resistance, Viral" by people in this website by year, and whether "Drug Resistance, Viral" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2003 | 3 | 2 | 5 | | 2004 | 1 | 4 | 5 | | 2005 | 2 | 2 | 4 | | 2006 | 2 | 2 | 4 | | 2007 | 2 | 2 | 4 | | 2008 | 3 | 2 | 5 | | 2009 | 2 | 2 | 4 | | 2010 | 1 | 3 | 4 | | 2011 | 0 | 4 | 4 | | 2012 | 2 | 3 | 5 | | 2013 | 2 | 0 | 2 | | 2014 | 3 | 5 | 8 | | 2015 | 1 | 3 | 4 | | 2016 | 3 | 2 | 5 | | 2017 | 3 | 4 | 7 | | 2018 | 1 | 1 | 2 | | 2019 | 1 | 0 | 1 | | 2020 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 | | 2024 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Resistance, Viral" by people in Profiles.
-
Dinh T, Tber Z, Rey JS, Mengshetti S, Annamalai AS, Haney R, Briganti L, Amblard F, Fuchs JR, Cherepanov P, Kim K, Schinazi RF, Perilla JR, Kim B, Kvaratskhelia M. The structural and mechanistic bases for the viral resistance to allosteric HIV-1 integrase inhibitor pirmitegravir. mBio. 2024 Nov 13; 15(11):e0046524.
-
Abuogi L, Oyaro P, Wakjira G, Thomas KK, Scallon AJ, Mukui I, Chohan BH, Brown E, Karauki E, Yongo N, Ahmed B, Hassan SA, Wagude J, Kinywa E, Otieno L, Kingwara L, Oyaro B, Frenkel LM, John-Stewart G, Patel RC. HIV Drug Resistance Patterns and Characteristics Associated with Clinically Significant Drug Resistance among Children with Virologic Failure on Antiretroviral Treatment in Kenya: Findings from the Opt4Kids Randomized Controlled Trial. Viruses. 2023 10 12; 15(10).
-
Rubin EJ, Baden LR, Barocas JA, Morrissey S. Audio Interview: Addressing the Omicron Variant of SARS-CoV-2. N Engl J Med. 2022 Jan 27; 386(4):e16.
-
Kempf BJ, Watkins CL, Peersen OB, Barton DJ. An Extended Primer Grip of Picornavirus Polymerase Facilitates Sexual RNA Replication Mechanisms. J Virol. 2020 07 30; 94(16).
-
Rana AI, Castillo-Mancilla JR, Tashima KT, Landovitz RL. Advances in Long-Acting Agents for the Treatment of HIV Infection. Drugs. 2020 Apr; 80(6):535-545.
-
Yager JL, Coyle RP, Coleman SS, Ellison L, Zheng JH, Bushman L, Gardner EM, Morrow M, MaWhinney S, Anderson PL, Justice Kiser J, Castillo-Mancilla JR. Moderately High Tenofovir Diphosphate in Dried Blood Spots Indicates Drug Resistance in Viremic Persons Living with HIV. J Int Assoc Provid AIDS Care. 2019 Jan-Dec; 18:2325958219888457.
-
Murray KF, Balistreri WF, Bansal S, Whitworth S, Evans HM, Gonzalez-Peralta RP, Wen J, Massetto B, Kersey K, Shao J, Garrison KL, Parhy B, Brainard DM, Arnon R, Gillis LA, Jonas MM, Lin CH, Narkewicz MR, Schwarz K, Rosenthal P. Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11. Hepatology. 2018 12; 68(6):2158-2166.
-
Wyles D, Mangia A, Cheng W, Shafran S, Schwabe C, Ouyang W, Hedskog C, McNally J, Brainard DM, Doehle BP, Svarovskaia E, Miller MD, Mo H, Dvory-Sobol H. Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir. Antivir Ther. 2018; 23(3):229-238.
-
Wyles DL. Resistance to DAAs: When to Look and When It Matters. Curr HIV/AIDS Rep. 2017 12; 14(6):229-237.
-
Koullias Y, Sax PE, Fields NF, Walensky RP, Hyle EP. Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus? Clin Infect Dis. 2017 10 15; 65(8):1274-1281.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|